In the I-SPY 1 breast cancer clinical trial, change in size of the primary in-breast tumor in response to neoadjuvant therapy was a strong predictor of pathologic complete response. In this study, I-SPY 1 MRI lymph node characteristics was studied. Lymph nodes of patients who achieved pathologic complete response after chemotherapy had different characteristics from those who have residual disease in the tumor bed. The percent change of the signal enhancement ratio of each individual lymph node was the best parameter to differentiate between pathologic complete responders versus incomplete or non-responders.
This abstract and the presentation materials are available to members only; a login is required.